262 related articles for article (PubMed ID: 33787516)
1. Prevalence of COVID-19 Virus Infection in Semnan province.
Jandaghi E; Hemati M; Mohammadlou M; Jandaghi J; Mirmohammadkhani M; Danaei N; Kokhaei P
Iran J Immunol; 2021 Mar; 18(1):74-81. PubMed ID: 33787516
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
[TBL] [Abstract][Full Text] [Related]
3. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
[TBL] [Abstract][Full Text] [Related]
5. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
[TBL] [Abstract][Full Text] [Related]
6. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020.
Shakiba M; Nazemipour M; Salari A; Mehrabian F; Nazari SSH; Rezvani SM; Ghasempour Z; Heidarzadeh A; Mansournia MA
Emerg Infect Dis; 2021 Feb; 27(2):636-638. PubMed ID: 33349310
[TBL] [Abstract][Full Text] [Related]
7. Seroprevalence of Immunoglobulin M and G Antibodies against SARS-CoV-2 Virus: A Systematic Review and Meta-Analysis Study.
Fathi M; Vakili K; Sayehmiri F; Mohamadkhani A; Ghanbari R; Hajiesmaeili M; Rezaei-Tavirani M
Iran J Immunol; 2021 Mar; 18(1):34-46. PubMed ID: 33787512
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of Anti-SARS-CoV-2 Specific Antibodies in Health-Care Workers Compared to General Population during an Early Phase of the Pandemic, Tehran-Iran.
Mortezagholi S; Rostamzadeh D; Alinejad M; Younesi V; Tabarsi P; Shabani M
Iran J Immunol; 2021 Mar; 18(1):82-92. PubMed ID: 33787517
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with a high incidence of COVID-19 cases: a population-based study.
Stefanelli P; Bella A; Fedele G; Pancheri S; Leone P; Vacca P; Neri A; Carannante A; Fazio C; Benedetti E; Fiore S; Fabiani C; Simmaco M; Santino I; Zuccali MG; Bizzarri G; Magnoni R; Benetollo PP; Merler S; Brusaferro S; Rezza G; Ferro A
Clin Microbiol Infect; 2021 Apr; 27(4):633.e1-633.e7. PubMed ID: 33253941
[TBL] [Abstract][Full Text] [Related]
11. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of serum IgM and IgG antibodies in COVID-19 patients by enzyme linked immunosorbent assay.
Zhou C; Bu G; Sun Y; Ren C; Qu M; Gao Y; Zhu Y; Wang L; Sun L; Liu Y
J Med Virol; 2021 May; 93(5):2857-2866. PubMed ID: 33331654
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.
Ristić M; Milosavljević B; Vapa S; Marković M; Petrović V
PLoS One; 2021; 16(7):e0254516. PubMed ID: 34242377
[TBL] [Abstract][Full Text] [Related]
14. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves.
Boon SS; Wong MCS; Ng RWY; Leung DTM; Chen Z; Lai CKC; Ho WCS; Huang J; Wong BKC; Fung KSC; Chan PKS
JAMA Netw Open; 2021 Nov; 4(11):e2132923. PubMed ID: 34779848
[TBL] [Abstract][Full Text] [Related]
16. Highlighted Prospects of an IgM/IgG Antibodies Test in Identifying Individuals With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
Li Y; He Q; Yu R; Jiang H; Wang W; Feng D; Hou G; Zhou H; Jiang Y; Xiang Z
Arch Pathol Lab Med; 2021 Jan; 145(1):39-45. PubMed ID: 32966561
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany.
Tönshoff B; Müller B; Elling R; Renk H; Meissner P; Hengel H; Garbade SF; Kieser M; Jeltsch K; Grulich-Henn J; Euler J; Stich M; Chobanyan-Jürgens K; Zernickel M; Janda A; Wölfle L; Stamminger T; Iftner T; Ganzenmueller T; Schmitt C; Görne T; Laketa V; Olberg S; Plaszczyca A; Cortese M; Bartenschlager R; Pape C; Remme R; Huzly D; Panning M; Weigang S; Giese S; Ciminski K; Ankerhold J; Kochs G; Schwemmle M; Handgretinger R; Niemeyer CM; Engel C; Kern WV; Hoffmann GF; Franz AR; Henneke P; Debatin KM; Kräusslich HG
JAMA Pediatr; 2021 Jun; 175(6):586-593. PubMed ID: 33480966
[TBL] [Abstract][Full Text] [Related]
18. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
[TBL] [Abstract][Full Text] [Related]
19. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
